Your session is about to expire
← Back to Search
Anti-cancer Agent
Treatment for Breast Cancer
N/A
Recruiting
Led By Leslie Montgomery, MD
Research Sponsored by Hackensack Meridian Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up completion of chemotherapy, approximately 18 weeks.
Awards & highlights
No Placebo-Only Group
Summary
The probability of pCR in TNBC patients receiving standard of care neoadjuvant chemotherapy treatment is associated with the dominance of specific intestinal and intratumoral microbiota that promote anti-tumor immunosurveillance.
Eligible Conditions
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ completion of chemotherapy, approximately 18 weeks.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~completion of chemotherapy, approximately 18 weeks.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Pathologic Complete Response
Secondary study objectives
Other Correlations between Pathologic complete Response
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Find a Location
Who is running the clinical trial?
Hackensack Meridian HealthLead Sponsor
135 Previous Clinical Trials
30,253 Total Patients Enrolled
7 Trials studying Breast Cancer
2,304 Patients Enrolled for Breast Cancer
Breast Cancer Research FoundationOTHER
71 Previous Clinical Trials
137,774 Total Patients Enrolled
42 Trials studying Breast Cancer
130,509 Patients Enrolled for Breast Cancer
Leslie Montgomery, MDPrincipal InvestigatorHackensack UMC
1 Previous Clinical Trials
13 Total Patients Enrolled
1 Trials studying Breast Cancer
13 Patients Enrolled for Breast Cancer
Share this study with friends
Copy Link
Messenger